Barclays’s Acceleron Pharma XLRN Stock Holding History

Barclays’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-111,000	Closed	-$5.17M	–	7453
2019 Q1	$5.17M	Buy	+111,000	New	+$4.87M	﹤0.01%	1640
2018 Q3	–	Sell	-33,000	Closed	-$1.6M	–	7538
2018 Q2	$1.6M	Buy	33,000 +3,000	+10%	+$109K	﹤0.01%	2778
2018 Q1	$1.17M	Buy	+30,000	New	+$1.28M	﹤0.01%	3020

Barclays's XLRN Position: Q4 2021 in Review

Barclays sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 111,461 shares — an estimated $19.2M sold.

Barclays first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $19.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Barclays reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Barclays sold 111,461 Acceleron Pharma shares in Q4 2021, an estimated $19.2M.
Barclays first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
Barclays's Acceleron Pharma position peaked at $19.2M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.